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Introduction {#sec005}
============

The discovery of the anti-inflammatory and antioxidant properties of high density lipoproteins (HDL) has led to the question of whether HDL can be used therapeutically to treat inflammation in disease. Insulin resistance is critically dependent on liver inflammation with studies showing that constitutively active hepatic nuclear factor-kappaB (NF-κB), the central mediator driving the inflammatory response, leads to an insulin resistant state in a mouse model \[[@pone.0226931.ref001]\]. We previously demonstrated that administration of apolipoprotein A-I (apoA-I), either independently (lipid free) or as part of a reconstituted HDL with (rHDL) containing PLPC protects against liver inflammation and improves insulin resistance in high-fat fed C57Bl/6 mice \[[@pone.0226931.ref002]\]. Whilst the results are promising, the generation of apoA-I particles are large and time consuming.

Apolipoprotein A-I (apoA-I) mimetic peptides have been developed and designed to function similarly to full length apoA-I, with greater potency and a better pharmacokinetic profile than full length apoA-I \[[@pone.0226931.ref003],[@pone.0226931.ref004]\]. These mimetic peptides offer many advantages over rHDL including the relative low cost, simplicity of production and the ability to modify their structure to allow oral administration. ApoA-I mimetic peptides are characterized by their phenylalanine residue attachments, with an increase in phenyalanine residue correlating with increasing hydrophobicity and their ability to associate with phospholipids \[[@pone.0226931.ref004]\]. Based on the number of hydrophobic phenylalanine residues in the sequence, the most well studied are the 4F and 5F apoA-I mimetic peptides. These have the same class A amphiphatic helical structure as apoA-I \[[@pone.0226931.ref005]\]. D-4F and L-5F differ from each other with respect to the number of phenylalanines present on the hydrophobic face of the amphiphatic helix and that D-4F is synthesized from D-amino acids while L-5F is synthesized from L-amino acids. For oral administration, D-amino acids have been found to resist enzymatic degradation compared to L-amino acids. However, after absorption, D-amino acids would remain undegraded that can lead to toxicity and other side effects \[[@pone.0226931.ref006]\]. L-amino acids are less toxic in the circulation however they are not resistant to enzymatic degradation via oral administration. Both have been used previously in biological studies with reported potent anti-inflammatory and antioxidant effects \[[@pone.0226931.ref007]--[@pone.0226931.ref012]\].

In the present study we tested directly whether treatment with the apoAI mimetic peptides, D-4F and L-5F, can improve insulin sensitivity associated with decreased hepatic inflammation in high fat diet (HFD)-fed mice. We show that the mimetic treatments are remarkably effective at decreasing hepatic inflammation and improving insulin sensitivity. The efficacy of the mimetic peptides is similar to what we have previously published for rHDLs \[[@pone.0226931.ref002]\].

Materials and methods {#sec006}
=====================

Mimetic peptides {#sec007}
----------------

The N-terminal acetylated and C-terminal amidated apoA-I mimetic peptides were purchased from ChinaPeptides (Shanghai, China). The "4F" denotes the peptide: Ac-D-W-F-K-A-F-Y-D-K-VA-E-K-F-K-E-A-F-NH~2~ synthesized from D-amino acids (D-4F). The "5F" denotes the peptide: Ac-D-W-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-NH~2~, synthesized from L-amino acids. Lyophilized peptide was stored at -20°C and solubilized in sterile saline immediately prior to use.

Animal model of high fat diet-induced insulin resistance {#sec008}
--------------------------------------------------------

To prove the concept, males were used in this study as they are not affected by periodical changes in sex hormones. Forty 6-week old male C57Bl/6 mice were obtained from the Australian BioResources (Moss Vale, NSW, Australia) and housed in a 12-hour light/12-hour dark cycle with food and water available *ad libitum*. Of the 40 mice, 10 were fed a normal chow diet (12% fat; 14 MJ/kg, Specialty Feeds, NSW, Australia), and 30 mice were fed a high fat diet (43% fat; 20 MJ/kg, SF03-020, Specialty Feeds, WA, Australia). The HFD has been repeatedly used to induce obesity in rodents by us \[[@pone.0226931.ref002],[@pone.0226931.ref013]\]. At 16 weeks of age, when all HFD-fed mice had established insulin resistance, the mice were subdivided with 10 subsequently treated with D-4F (300 μg/mL \[[@pone.0226931.ref014]\] in drinking water), another 10 were treated with L-5F (10 mg/kg \[[@pone.0226931.ref014]\] i.p injection twice per week) and another 10 were administered endotoxin-free saline as the vehicle control until 21 weeks of age. Body weights were recorded weekly. All animals were administered their last peptide dose 24 hr before euthanasia by cardiac puncture after full anaesthesia has been achieved using isoflurane. At sacrifice, serum was collected and stored at --20°C. Liver, visceral and epididymal fat pads were then carefully excised, weighed, snap frozen in liquid nitrogen and stored at --80°C. All animal experiments were conducted in accordance to the guidelines described by the Australian National Health and Medical Research council code of conduct for animals with approval from the University of Technology Sydney Animal Care and Ethics Committee, Sydney, NSW, Australia (ACEC\#ETH11-442A).

Glucose and insulin tolerance test {#sec009}
----------------------------------

Intraperitoneal (i.p.) glucose tolerance tests (GTT) and intraperitoneal insulin tolerance tests (ITT) were performed in overnight fasted mice, as previously described \[[@pone.0226931.ref002]\]. Briefly, animals were injected i.p. with 2 g/kg of D-Glucose (Sigma Aldrich, St Louis, MO, USA) for the GTT or with 0.5 IU/kg of insulin (Humulin, Lilly, France) for the ITT. Blood glucose levels were measured (Accu-Chek, Roche, Castle Hill, NSW, Australia) at indicated times. The area under the curve (AUC) of glucose levels was calculated for each mouse.

Insulin and lipid analysis {#sec010}
--------------------------

Serum insulin levels were measured by ELISA (Crystal Chem, Downers Grove, IL, USA). Serum and tissue triglyceride levels were measured using triglyceride reagent (Roche Diagnostics, Castle Hill, NSW, Australia) after lipids were extracted from tissue using a mixture of chloroform and methanol (2:1, v:v) as previously described \[[@pone.0226931.ref002]\]. Serum NEFA levels were measured using a commercially available kit (WAKO, Osaka, Japan).

RNA isolation and RT-qPCR {#sec011}
-------------------------

Total RNA was isolated from tissue using TRIsure (Bioline, Eveleigh, NSW, Australia) and bioanalysis was done using the Experion system (Bio-Rad, Hercules, CA). cDNA was reverse transcribed from total RNA (200 ng) using the SensiFAST cDNA synthesis kit (Bioline) and gene expression determined by qPCR (CFX96, Bio-Rad), using specific primers described previously \[[@pone.0226931.ref002]\]. Relative change in mRNA gene expression was determined as described previously, using ubiquitin C (UBC) as the reference gene (3). The average value of the control was assigned as the calibrator, against which all other samples were expressed as percentage difference.

Statistical analysis {#sec012}
--------------------

All values are reported as mean ± standard error of mean (SEM). Significant differences in treatments was determined by one-way ANOVA with Bonferroni's posthoc test using GraphPad Prism 6 (La Jolla, CA, USA). *P* \<0.05 was considered significant.

Results {#sec013}
=======

D-4F or L-5F did not attenuate weight gain in high fat diet-fed C57BL/6 mice {#sec014}
----------------------------------------------------------------------------

In this study, C57Bl/6 mice were fed a standard chow-diet (ND) or a high fat diet (HFD) *ad libitum* that was intended to induce a large weight gain, dyslipidemia and insulin resistance \[[@pone.0226931.ref015]\]. After 10-weeks on the diet, HFD-fed mice were randomly assigned to apolipoprotein AI mimetic peptides, D-4F or L-5F, treatment. [Fig 1A](#pone.0226931.g001){ref-type="fig"} shows the time course of body weight gain during the 16 weeks of HFD with or without D-4F or L-5F treatment. As expected, after 16 weeks, body weight was significantly increased in all mice on HFD compared with ND (*P*\<0.001). The increase in body weight was associated with increased liver weight (*P*\<0.001; [Fig 1B](#pone.0226931.g001){ref-type="fig"}), visceral fat weight (*P*\<0.0001; [Fig 1C](#pone.0226931.g001){ref-type="fig"}) and subcutaneous fat weight (*P*\<0.0001; [Fig 1D](#pone.0226931.g001){ref-type="fig"}). Treatment with D-4F or L-5F peptides did not reduce the HFD-induced body, liver or adipose tissue weight gain.

![D-4F and L-5F did not affect body, liver and adipose tissue weight gain.\
Weight of body (A), liver (B), visceral fat (C) and subcutaneous fat (D). Results are mean ± SEM (n = 8--10). \**P*\<0.05 vs. ND; \**P*\<0.001 vs. ND; \**P*\<0.0001 vs. ND.](pone.0226931.g001){#pone.0226931.g001}

D-4F and L-5F attenuate hepatic triglyceride accumulation {#sec015}
---------------------------------------------------------

The increase in body weight, liver weight and fat mass in response to the HFD was associated with increased hepatic triglycerides compared to normal controls (*P*\<0.05; [Fig 2A](#pone.0226931.g002){ref-type="fig"}), however both D-4F and L-5F treatment brought triglyceride levels back to baseline. The increase in hepatic triglyceride levels did not result in systemically high triglycerides ([Fig 2B](#pone.0226931.g002){ref-type="fig"}), however it was associated with an increase in serum NEFA by 22±13% (*P*\<0.05; [Fig 2C](#pone.0226931.g002){ref-type="fig"}), an effect that was not blocked by either D-4F or L-5F.

![D-4F and L-5F attenuate hepatic triglyceride accumulation.\
Hepatic triglyceride (A), serum triglyceride (B) and serum NEFA (C). Results are mean ± SEM (n = 8--10). †*P*\<0.05 vs. ND; \**P*\<0.05 vs. HFD.](pone.0226931.g002){#pone.0226931.g002}

Excess dietary carbohydrates are converted to triglycerides in the liver through the pathway of *de novo* lipogenesis for long-term energy storage. Enzymes involved in *de novo* lipogenesis are induced by key transcriptional regulators including sterol regulatory element binding protein 1c (*SREBP-1c*) and carbohydrate responsive element binding protein (*ChREBP*). In agreement with the increased hepatic triglyceride levels in HFD-fed mice, *SREBP-1c* and *ChREBP* mRNA levels increased in these mice (*P*\<0.001). Both D-4F and L-5F treatment decreased HFD-induced *SREBP-1c* (*P*\<0.001) and *ChREBP* (*P*\<0.001) mRNA levels. This observation suggests that mimetic treatment suppressed HFD-induced lipogenesis ([Fig 3A and 3B](#pone.0226931.g003){ref-type="fig"}).

![D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis.\
Quantitative real-time PCR of key genes involved in lipogenesis (A) SREBP-1c and (B) ChREBP. mRNA levels were normalized to Ubiquitin C (UBC). Results are mean ± SEM (n = 8--10). †*P*\<0.001 vs. ND; \*\**P*\<0.001 vs. HFD.](pone.0226931.g003){#pone.0226931.g003}

D-4F and L-5F effects on glucose- and insulin tolerance {#sec016}
-------------------------------------------------------

To determine the glucose tolerance of HFD-fed mice before treatment started with D-4F or L-5F, a GTT was performed. During the GTT, there was a significant increase in plasma glucose levels in HFD- vs. ND- fed mice ([Fig 4A and 4C](#pone.0226931.g004){ref-type="fig"}). Treatment with D-4F significantly improved glucose clearance compared to the HFD group as shown by a decrease in AUC compared to HFD (*P*\<0.05, [Fig 4B and 4D](#pone.0226931.g004){ref-type="fig"}). No significance was found for the AUC in the group treated with L-5F ([Fig 4D](#pone.0226931.g004){ref-type="fig"}).

![D-4F and L-5F improves blood glucose.\
Beginning at 6 weeks of age, C57BL/6 mice were fed a standard chow diet (ND) or high-fat diet for a total of 16 weeks. After 10 weeks, the high fat diet group was subdivided: HFD+endotoxin-free saline (HFD); HFD+D-4F (D-4F) or HFD+L-5F (L-5F) for the last 6 weeks of diet. Plasma glucose concentrations during intraperitoneal glucose tolerance test (GTT; glucose 2g/kg) (A) before treatment commenced and (B) after 4 weeks of treatment with the mimetic peptides. (C and D) Area under the curve for glucose (AUC glucose) was calculated using the trapezoid rule. Results are mean ± SEM (n = 8--10). †*P*\<0.05 vs. ND; \**P*\<0.05 vs. HFD.](pone.0226931.g004){#pone.0226931.g004}

To assess the amount of insulin secreted in response to glucose, serum insulin levels were measured at various time points during glucose tolerance testing. The results show hyperinsulinemia in the HFD and L-5F group compared to ND. Treatment with D-4F, but not L-5F, normalized insulin levels compared to the HFD group ([Fig 5A and 5B](#pone.0226931.g005){ref-type="fig"}).

![D-4F normalizes insulin levels.\
Beginning at 6 weeks of age, C57BL/6 mice were fed a standard chow diet (ND) or high-fat diet for a total of 16 weeks. After 10 weeks, the high fat diet group was subdivided: HFD+endotoxin-free saline (HFD); HFD+D-4F (D-4F) or HFD+L-5F (L-5F) for the last 6 weeks of diet. (A) Serum insulin levels were measured at various timepoints during the intraperitoneal glucose tolerance test (GTT; glucose 2g/kg). (B) Area under the curve for glucose (AUC glucose) was calculated using the trapezoid rule. Results are mean ± SEM (n = 4--6). †*P*\<0.05 vs. ND; \**P*\<0.05 vs. HFD.](pone.0226931.g005){#pone.0226931.g005}

Prior to treatment with D-4F or L-5F, insulin resistance of HFD-fed mice was assessed by an ITT. Insulin resistance was increased in the HFD group as shown by a higher AUC in all groups compared to ND ([Fig 6A and 6C](#pone.0226931.g006){ref-type="fig"}). Treatment with D-4F and L-5F improved insulin sensitivity (*P*\<0.05, [Fig 6B and 6D](#pone.0226931.g006){ref-type="fig"}).

![D-4F and L-5F improves insulin sensitivity.\
Beginning at 6 weeks of age, C57BL/6 mice were fed a standard chow diet (ND) or high-fat diet for a total of 16 weeks. After 10 weeks, the high fat diet group was subdivided: HFD+endotoxin-free saline (HFD); HFD+D-4F (D-4F) or HFD+L-5F (L-5F) for the last 6 weeks of diet. Plasma glucose concentrations during intraperitoneal insulin tolerance test (ITT; insulin 0.5 IU/kg) (A) before treatment commenced and (B) after 5 weeks of treatment with the mimetic peptides. (C and D) Area under the curve for glucose (AUC glucose) was calculated using the trapezoid rule. Results are mean ± SEM (n = 8--10). †*P*\<0.05 vs. ND; \**P*\<0.05 vs. HFD.](pone.0226931.g006){#pone.0226931.g006}

D-4F and L-5F suppress hepatic mRNA levels of gluconeogenesis- and lipogenic associated genes {#sec017}
---------------------------------------------------------------------------------------------

So far, our results, have indicated that D-4F and L-5F restores, at least in part, the disrupted glucose and insulin homeostasis induced by a HFD. It has previously been established that a HFD disrupts liver gluconeogenesis \[[@pone.0226931.ref016]\]. We, therefore, next tested if HFD affected the expression of the gluconeogenesis rate-limiting enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), and whether D-4F and L-5F treatment alleviated any HFD effect. Our findings show that indeed HFD increased PEPCK (*P*\<0.05 vs. ND) and G6Pase (*P*\<0.001 vs ND) expression and that both D-4F and L-5F restored PEPCK and G6Pase levels back to baseline. These findings for PEPCK and G6Pase are in keeping with their effect on improved glucose tolerance ([Fig 7A and 7B](#pone.0226931.g007){ref-type="fig"}).

![D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis.\
RT-qPCR of gluconeogenic enzymes (A) PEPCK and (B) G6Pase. mRNA levels were normalized to Ubiquitin C (UBC). Results are mean ± SEM (n = 8--10). †*P*\<0.05 vs. ND; ††*P*\<0.001 vs. ND; \*\**P*\<0.001 vs. HFD.](pone.0226931.g007){#pone.0226931.g007}

D-4F and L-5F suppress hepatic inflammation {#sec018}
-------------------------------------------

We have recently published that the improvement in insulin sensitivity in HFD-fed mice treated with rHDLs was associated with decreased hepatic inflammation \[[@pone.0226931.ref002]\]. We next tested whether D-4F and L-5F treatment could mimic this beneficial effect of rHDLs and also decrease hepatic inflammation as evidenced by decreased expression of key inflammatory markers, namely the cytokines, SAA1, IL-1β, IFN-γ and TNF-α. [Fig 8](#pone.0226931.g008){ref-type="fig"} show that HFD significantly increased the expression of all four cytokines (IL-1β and IFNϒ, *P*\<0.05; SAA1 and TNFα, *P*\<0.001 vs ND); an effect that was abrogated by both D-4F and L-5F (*P*\<0.001---*P*\<0.0001 vs. HFD).

![D-4F and L-5F decrease hepatic mRNA level of genes involved in inflammation.\
RTqPCR of genes involved in inflammation in the liver. mRNA levels were normalized to Ubiquitin C (UBC). Results are mean ± SEM (n = 8--10). †*P*\<0.05 vs. ND; ††*P*\<0.001 vs. ND; \*\**P*\<0.001 vs. HFD; \*\*\**P*\<0.0001 vs. HFD.](pone.0226931.g008){#pone.0226931.g008}

D-4F and L-5F suppress hepatic macrophage infiltration {#sec019}
------------------------------------------------------

The involvement of hepatic macrophages or Kupffer cells in the pathogenesis of insulin resistance has been previously reported \[[@pone.0226931.ref001],[@pone.0226931.ref016]\]. We next examined macrophage-specific gene expression levels in the liver as markers of macrophage infiltration. Our results show mRNA levels of *F4/80* (also known as *Emr1*) and *CD68* were upregulated in HFD-mice (*P*\<0.001; [Fig 9](#pone.0226931.g009){ref-type="fig"}). The expression of both genes were decreased by both D-4F (*P*\<0.001) and L-4F (*P*\<0.001).

![D-4F and L-5F decrease hepatic mRNA levels of monocyte-macrophage markers.\
RTqPCR of monocyte-macrophage markers in the liver. mRNA levels were normalized to Ubiquitin C (UBC). Results are mean ± SEM (n = 8--10). ††*P*\<0.001 vs. ND; \*\**P*\<0.001 vs. HFD.](pone.0226931.g009){#pone.0226931.g009}

Discussion {#sec020}
==========

Previous studies have revealed that chronic inflammation in hepatocytes is sufficient to drive the onset of insulin resistance, and that treatment of HFD-fed mice with reconstituted HDLs rescued insulin resistance associated with suppressed hepatic inflammation \[[@pone.0226931.ref001],[@pone.0226931.ref002]\]. Despite the successful treatment with rHDLs, its use as a feasible (cost, ease of production and administration) long-term clinical therapeutic option is not great. In the current study, we investigated whether the apoA-I mimetic peptides, D-4F and L-5F, were effective against HFD-induced insulin resistance. We uncovered three important findings. The first is that treatment of mice twice a week for four-weeks with D-4F was effective against the development of HFD glucose intolerance, the latter which is recognized as a first step towards type 2 diabetes. Treatment of mice with the peptides was also sufficient to markedly improve insulin sensitivity and importantly, the degree of improvement was in keeping with what was reported by us for mice treated in the same manner with rHDLs \[[@pone.0226931.ref002]\].

A second important finding is that the five-week treatment with either D-4F or L-5F suppressed hepatic inflammation. Cai *et al* report that chronic NF-κB activation in the liver of C57Bl/6 mice drives the onset of insulin resistance, even in the absence of a HFD \[[@pone.0226931.ref001]\]. Conversely, mice that express the inhibitor of NF-κB, IκB, do not develop insulin resistance, even when fed a HFD \[[@pone.0226931.ref001]\]. The fact that both D-4F and L-5F reduce hepatic inflammation, as demonstrated by decreased inflammatory cytokine expression and macrophage infiltration, suggest that a reduction in local inflammation within the liver may serve as an underlying mechanism by which HDL-based therapies can improve insulin resistance.

The third important finding is that D-4F and L-5F decrease hepatic lipid accumulation. These findings suggest that D-4F and L-5F interfere with hepatic *de novo* lipid synthesis by directly decreasing SREBP1c levels, a transcription factor that can promote lipid production in the liver. This scenario is plausible because our findings show that both D-4F and L-5F decreased hepatic triglyceride levels, despite no change occurring in serum triglyceride concentrations. An additional observation that lends support to the notion that D-4F and L-5F might play a direct role in decreasing hepatic lipid accumulation is that D-4F and L-5F both decreased hepatic SREBP-1c and ChREBP expression, enzymes involved in *de novo* fatty acid biosynthesis.

In the present study, we used C57Bl/6 mice to investigate D-4F and L-5F effects on improving HFD-induced insulin resistance. Our findings in this study are in keeping with our previous reports for rHDLs and that of Peterson *et al* who demonstrated L-4F treatment improved insulin sensitivity and improved glucose tolerance in the *ob/ob* mouse model of diabetes \[[@pone.0226931.ref017]\]. Peterson *et al* showed that L-4F treatment increased serum adiponectin levels, which likely resulted in the reduction of fat content in the liver, that was a primary observation of their study \[[@pone.0226931.ref017]\]. In our study, we did not measure adiponectin levels, however no changes in fat content were noted for either D-4F or L-5F treatments.

Despite the positive effect that L-5F had on insulin resistance, it was not as effective at improving glucose tolerance when compared to D-4F, even though a trend towards improvement was observed. Insulin levels during glucose tolerance testing showed the cohort of mice treated with L-5F had hyperinsulinemia similar to that of HFD-fed mice despite L-5F showing improved insulin sensitivity in the insulin tolerance test. This suggests that endogenous insulin secreted during the GTT in the L-5F cohort is not as effective compared to the ND or the cohort treated with D-4F suggesting insulin receptor levels, or other metabolic parameters, are not restored by L-5F. The differential responses of D-4F and L-5F need further investigation to fully understand the differences in their mechanism of action. The strong effects of D-4F are interesting given previous studies that show that the bioavailability of this mimetic in plasma is poor (\<1%, \[[@pone.0226931.ref018]\]). It has been proposed that D-4F exerts its effects via the binding of D4F to oxidized lipids in the intestine. The D4F interaction with oxidized lipids leads to their inactivation ultimately associated with decreased systemic inflammation \[[@pone.0226931.ref019]\]. L5F is injected rather than ingested orally, and is therefore unable to induce anti-inflammatory effects in the intestine, with subsequent less effectiveness. Such intestine-led anti-inflammatory effects could help explain the divergent effects of D-4F and L-5F in our study.

While our findings for D-4F are in keeping with our previous reports for rHDLs \[[@pone.0226931.ref015]\] and Peterson et al \[[@pone.0226931.ref017]\], they contrast with those reported by Averill *et al* for L-4F in the *Ldlr*^-/-^ mouse model \[[@pone.0226931.ref020]\]. In these mice, L-4F failed to improve insulin resistance or adipocyte inflammation. There are a number of differences that could explain the conflicting results including the form of 4F that was used. In our study, the D form that is stable for oral delivery was used while the L form was used in the *Ldlr*^*-/-*^ mice and this requires injection. This suggests that there may be differences in bioavailability of D-4F vs L-4F/L-5F, which are working via a different mechanism of action. Another difference may be that C57Bl/6 mouse strains are more sensitive, and *Ldlr*^*-/-*^ more resistant, to apoA-I mimetic peptides. There is evidence that dosages used in *Ldlr*^*-/-*^ mice that have successfully suppressed inflammation were 9--25 times higher \[[@pone.0226931.ref021]--[@pone.0226931.ref023]\] than the dose used in the Averill *et al* study \[[@pone.0226931.ref020]\]. Therefore, future studies should consider using multiple models of insulin resistance (genetic and diet) to better characterize the protective capacity of apoA-I mimetic peptides against insulin resistance.

Reduced levels of circulating HDLs and apoA-I are very common in the diabetic population \[[@pone.0226931.ref024]\]. Whilst the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial failed to show improvements in cardiovascular disease, increased HDL levels as a result of treatment with torcetrapib reduced plasma glucose, insulin and IR by homeostatic model assessment in patients, suggesting increased HDL levels may improve IR \[[@pone.0226931.ref024]\]. The mechanisms accounting for the actions of increased HDLs on IR are multiple and include actions in the pancreas, skeletal muscle and liver, as shown by us and others \[[@pone.0226931.ref002],[@pone.0226931.ref025],[@pone.0226931.ref026]\]. In this study, the D-4F-induced improvement in glucose clearance associated with suppression of liver inflammation. Whilst reduced liver inflammation may well underlie the systemic effect of improved glucose clearance, it is very likely that improved glucose clearance is a combined effect of D-4F on increased insulin secretion from pancreatic β cells \[[@pone.0226931.ref027]\], increased uptake of glucose by skeletal muscle cells \[[@pone.0226931.ref028]\], decreased inflammatory responses in coronary endothelium \[[@pone.0226931.ref029]\] and adipose tissue \[[@pone.0226931.ref030]\], as well as the decreased liver inflammation reported here.

In summary, our findings for the apoA-I mimetic peptides adds to the growing evidence supporting a strong relationship between apoA-I and HDL treatments and reduced inflammation, insulin resistance and type 2 diabetes in mouse models. Further research is now warranted to develop the best approach for targeting the HDL-based therapies to prevent or treat insulin resistance.

10.1371/journal.pone.0226931.r001
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The present manuscript has been described that D-4F and L-5F, the Apo-AI mimetic peptides treatment led to improved glucose homeostasis, and this effect is associated with reduced expression of inflammatory markers in the liver and reduced infiltration of macrophages, suggesting an overall suppression of hepatic inflammation.

These observations are interesting, and some specific point should be considered.

Specific comments

Authors have described only D-4F and L-5F as Apo-AI mimetic peptides, however various Apo-AI mimetic peptides have been developed so far. Authors should show about other peptides such as 5A, 18A, and FAMP\...

In addition to Apo-AI mimetic peptides, we also have reconstituted-HDL such as ApoA-1/POPC disc. Author should describe the difference between Apo-AI mimetic peptides and reconstituted-HDL.

In this study, the authors conducted i.p.GTT as an assessment of glucose tolerance, but this method neglected the effects of incretin. Is it not necessary to consider the effect of incretin on the results of this study?

CETP inhibitor, one of the HDL-targeting drug also improves glucose homeostasis. The authors should consider the difference in the mechanism between the effect of CETP inhibitor and the effect of Apo-AI mimetic peptides.

HOMA-IR and HOMA-beta should be shown.

Fig. 1A; 4A; 4B; 5A; 6A; 6B, It is very difficult to understand group differences in the line graphs.

Reviewer \#2: Interesting paper examining effect of apoA-I mimetic peptides (D4F and L5F) on glucose metabolism in C57BL6 mice fed a high fat diet.

1\. Abstract: Quantitative description of key findings and P-values should be added.

2\. Methods: Method used to quantify visceral and SQ fat should be stated. Time from. Last peptide dose for drawing plasma from mice should be stated.

3\. Lipoprotein analysis: Ideally, besides plasma triglycerides, total cholesterol should also be analyzed. A more detailed analysis of plasma lipoproteins would also be helpful.

4\. Discussion: Short paragraph should be added on potential mechanism of action of peptides in regard to observed effects. Oral D4F has been proposed to act via modulating oxidized lipid content in the intestine. This works should be cited and used to possibly explain effect of D4F and lack of effect of L5F. Should discuss how the magnitude of the effect on glucose metabolism by D4F compares to past studies on treatment with rHDL.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0226931.r002

Author response to Decision Letter 0

5 Dec 2019

Reviewer \#1: Manuscript Number: PONE-D-19-23129

Apoplipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice by Kristine Ching-Yee McGrath et al.

The present manuscript has been described that D-4F and L-5F, the Apo-AI mimetic peptides treatment led to improved glucose homeostasis, and this effect is associated with reduced expression of inflammatory markers in the liver and reduced infiltration of macrophages, suggesting an overall suppression of hepatic inflammation.

These observations are interesting, and some specific point should be considered.

1\. Authors have described only D-4F and L-5F as Apo-AI mimetic peptides, however various Apo-AI mimetic peptides have been developed so far. Authors should show about other peptides such as 5A, 18A, and FAMP\...

Response: With so many different mimetic peptide sequences exhibiting various degrees of activity, it is not possible to select lead sequences with confidence. Whilst it would be of great interest to investigate the effects of the other peptides, it would be challenging to include all of them in the one study. To address the reviewer's comment, we have now clarified this in the introduction section. Please see page 4, line 75-79.

2\. In addition to Apo-AI mimetic peptides, we also have reconstituted-HDL such as ApoA- 1/POPC disc. Author should describe the difference between Apo-AI mimetic peptides and reconstituted-HDL.

Response: The introduction has now been clarified to address the reviewer's comment. Please see page 4, line 66-70.

3\. In this study, the authors conducted i.p.GTT as an assessment of glucose tolerance, but this method neglected the effects of incretin. Is it not necessary to consider the effect of incretin on the results of this study?

Response: We thank the reviewer for this comment. Intraperitoneal glucose tolerance test in mice followed by measurement of glucose levels in the blood is widely used to give an indication of the presence or absence of diabetes or impairment of glucose tolerance. Whilst we agree that assessment of incretin hormones will value-add to our results, we did not measure incretin levels during our glucose tolerance test in this study but will certainly take this into consideration in our future experimentation.

4\. CETP inhibitor, one of the HDL-targeting drug also improves glucose homeostasis. The authors should consider the difference in the mechanism between the effect of CETP inhibitor and the effect of Apo-AI mimetic peptides.

Response: The discussion now addresses the reviewer's comment. Please see page 15, line 342-348.

5\. HOMA-IR and HOMA-beta should be shown.

Response: We thank the reviewer for this comment. The assessment of IR and B-cell function is commonly used in the clinic. The HOMA model however, has not been validated for use in rodents or any other animals, and such use violates the assumptions of the model. We have therefore chosen not to include these measurements for this study (Ref: Wallace TM, Levy JC, Matthews, DR. Use and Abuse of HOMA Modeling. Diabetes Care 27: 1487-1495, 2004).

6\. Fig. 1A; 4A; 4B; 5A; 6A; 6B, It is very difficult to understand group differences in the line graphs.

Response: To allow for differentiation between the groups, the lines have now been colour coded.

Reviewer \#2: Interesting paper examining effect of apoA-I mimetic peptides (D4F and L5F) on glucose metabolism in C57BL6 mice fed a high fat diet.

1\. Abstract: Quantitative description of key findings and P-values should be added.

Response: The abstract now includes quantitative description and P-values as requested.

2\. Methods: Method used to quantify visceral and SQ fat should be stated. Time from. Last peptide dose for drawing plasma from mice should be stated.

Response: The method used to quantify visceral and SQ fat has already been included in the methodology section on page 6, line 115-117. The time from last peptide dose have now been added on page 6, line 113-115.

3\. Lipoprotein analysis: Ideally, besides plasma triglycerides, total cholesterol should also be analyzed. A more detailed analysis of plasma lipoproteins would also be helpful.

Response: Unfortunately we do not have enough serum for further analysis as suggested. We thank the reviewer for this suggestion and will certainly consider this for future studies.

4\. Discussion: Short paragraph should be added on potential mechanism of action of peptides in regard to observed effects. Oral D4F has been proposed to act via modulating oxidized lipid content in the intestine. This works should be cited and used to possibly explain effect of D4F and lack of effect of L5F. Should discuss how the magnitude of the effect on glucose metabolism by D4F compares to past studies on treatment with rHDL.

Response: A discussion of this has now been included on page 14, line 319 - 326.

10.1371/journal.pone.0226931.r003
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